Alphamab Oncology (HKG:9966) said the Center for Drug Evaluation of China's National Medical Products Administration approved the new investigational drug application for its new anti-tumor drug after the phase I/II clinical trial, according to a Tuesday filing with the Hong Kong bourse.
JSKN033-102 is a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate and PD-L1 immune checkpoint inhibitor, the filing added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。